The estimated Net Worth of Paul Campanelli is at least $13.6 Million dollars as of 2 April 2021. Mr. Campanelli owns over 668,300 units of Endo International plc stock worth over $525,490 and over the last 9 years he sold ENDP stock worth over $0. In addition, he makes $13,118,300 as Chairman of the Board at Endo International plc.
Sign up
Mr. Campanelli ENDP stock SEC Form 4 insiders trading
Paul has made over 7 trades of the Endo International plc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 668,300 units of ENDP stock worth $195,545 on 2 April 2021.
The largest trade he's ever made was exercising 668,300 units of Endo International plc stock on 2 April 2021 worth over $195,545. On average, Paul trades about 34,578 units every 60 days since 2015. As of 2 April 2021 he still owns at least 1,795,934 units of Endo International plc stock.
You can see the complete history of Mr. Campanelli stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Paul Campanelli biography
Paul V. Campanelli has been appointed as Chairman of the Board of the Company effective 3/6/2020. Mr. Campanelli began his service as Director, Chief Executive Officer and President in September 2016. Mr. Campanelli joined Endo in 2015 as the President of Par Pharmaceutical, leading Endo’s fully integrated U.S. Generics business, following Endo’s acquisition of Par Pharmaceutical. Prior to joining Endo, he served as Chief Executive Officer of Par Pharmaceutical Companies, Inc. following the company’s September 2012 acquisition by TPG. Prior to the TPG acquisition, Mr. Campanelli served as Chief Operating Officer and President of Par Pharmaceutical, Inc. from 2010 to 2012. At Par Pharmaceutical Inc., Mr. Campanelli had also served as Senior Vice President, Business Development & Licensing; Executive Vice President and President of Par Pharmaceutical, Inc.; and was named a Corporate Officer by its board of directors. He also served on the board of directors of Sky Growth Holdings Corporation from 2012 until 2015. Prior to joining Par Pharmaceutical Companies, Inc., Mr. Campanelli served as Vice President, Business Development at Dr. Reddy’s Laboratories Ltd., where he was employed from 1992 to 2001. He currently serves on the board of directors of Pharmaceutical Associates Inc. Mr. Campanelli earned his Bachelor of Science degree from Springfield College. Mr. Campanelli’s qualifications to serve on the Board of Endo include, among others, his experience in leadership positions at pharmaceutical companies, including the role of chief executive officer, his in-depth knowledge of the pharmaceutical industry, the Company, its businesses and management as well as his judgment and strategic vision.
What is the salary of Paul Campanelli?
As the Chairman of the Board of Endo International plc, the total compensation of Paul Campanelli at Endo International plc is $13,118,300. There are no executives at Endo International plc getting paid more.
How old is Paul Campanelli?
Paul Campanelli is 58, he's been the Chairman of the Board of Endo International plc since 2020. There are 4 older and 12 younger executives at Endo International plc. The oldest executive at Endo International plc is Michael Hyatt, 74, who is the Independent Director.
What's Paul Campanelli's mailing address?
Paul's mailing address filed with the SEC is C/O CONVEY HEALTH SOLUTIONS, 100 SE THIRD AVENUE, 26TH FLOOR, FORT LAUDERDALE, FL, 33394.
Insiders trading at Endo International plc
Over the last 11 years, insiders at Endo International plc have traded over $3,455,441 worth of Endo International plc stock and bought 152,347 units worth $3,901,804 . The most active insiders traders include Silva Rajiv De, Paul Campanelli, and Shane Cooke. On average, Endo International plc executives and independent directors trade stock every 36 days with the average trade being worth of $12,163. The most recent stock trade was executed by Patrick A Barry on 29 March 2022, trading 59,298 units of ENDP stock currently worth $17,351.
What does Endo International plc do?
Endo is a specialty pharmaceutical company committed to helping everyone it serves live their best life through the delivery of quality, life-enhancing therapies. Its decades of proven success come from a global team of passionate employees collaborating to bring the best treatments forward. Together, it boldly transforms insights into treatments benefiting those who need them, when they need them.
What does Endo International plc's logo look like?
Complete history of Mr. Campanelli stock trades at Endo International plc and Convey Parent
Endo International plc executives and stock owners
Endo International plc executives and other stock owners filed with the SEC include:
-
Paul Campanelli,
Chairman of the Board -
Terrance Coughlin,
Chief Operating Officer, Executive Vice President -
Blaise Coleman,
Pres, CEO & Director -
Blaise Coleman,
President, Chief Executive Officer, Director -
Matthew Maletta,
Executive Vice President, Chief Legal Officer -
Patrick Barry,
Executive Vice President and Chief Commercial Officer, U.S. Branded Business -
Patrick A. Barry,
Exec. VP & Pres of Global Commercial Operations -
Mark T. Bradley,
Exec. VP & CFO -
Roger Kimmel,
Senior Independent Director -
Shane Cooke,
Independent Director -
William Montague,
Independent Director -
Nancy Hutson,
Independent Director -
Michael Hyatt,
Independent Director -
M. Christine Smith,
Independent Director -
Mark Barberio,
Independent Director -
Jack Boyle,
Senior Vice President - Financial Planning & Analysis, Chief Accounting Officer, Controller -
Rahul Garella,
Executive Vice President, International Pharmaceuticals -
Domenico Ciarico,
Executive Vice President and Chief Commercial Officer, Sterile and Generics -
Joseph A. Barbarite,
Exec. VP of Global Quality and Compliance -
Tracy Basso,
Chief HR Officer -
Susan Williamson,
Sr. VP & Chief Compliance Officer -
Laure E. Park,
Sr. VP of Investor Relations & Corp. Affairs -
Ruth Thorpe,
Sr. VP of Information Technology & Chief Information Officer -
Robert Polke,
Exec. VP & Global Head of Operations -
Arthur J Higgins,
Director -
Douglas S Ingram,
Director -
Hemanth Jacob Varghese,
Pres. International Pharma -
Suketu Upadhyay,
EVP, Chief Financial Officer -
Antonio R Pera,
President, Par Pharmaceutical -
Joseph Ciaffoni,
President, U.S. Branded Pharma -
Carrie Ann Nichol,
SVP, Controller & CAO -
Mark T. Bradley,
EVP, Chief Financial Officer -
Frank B. Raciti,
VP, Controller and CAO -
Daniel Rudio,
Vice President, Controller -
Sharad Mansukani,
Director -
William Spengler,
Director -
Silva Rajiv De,
President & CEO -
John Delucca,
Director -
Brian Lortie,
President Branded Pharma -
Susan Hall,
EVP, CSO, Global Head of R&D -
Caroline B Manogue,
Exec. V.P., CLO & Secy -
Camille Farhat,
President, AMS, Inc. -
Ivan P. Gergel,
EVP, R&D and CSO -
Donald W De Golyer,
Chief Operating Officer,Pharma -
Mary Christine Smith,
Director -
George Apostol,
EVP, Global R&D -
Jennifer M Chao,
Director -
James Patrick Tursi,
Executive VP, Global R&D